Current plan
Explorer
Upgrade
limit warning One or more limits reached
Daily profile views
0 / 3
Monthly profile views
0 / 15
Searches (last 30 days)
No linked companies
Get featured as a Team Member in a Finder company.
Team Member at
Add Entity
snc-logo

Startup Nation Finder

My Watchlists
Ecosystem
Startups
Investors
Hubs
Multinationals
Reports toggle reports submenu
Saved Searches
Following
Messaging
Notifications
About Us
Glossary
Current plan
Explorer
Pricing plans
warning Payment details required
Daily profile views
0 / 3
Monthly profile views
0 / 15
Searches (last 30 days)

Upgrade your Finder plan

  • Basic CSV download
  • Unlimited profile visits
  • Unlimited searches
  • Ecosystem reports
  • Saved searches, Watchlists & notifications

Create Watchlist

Watchlist name*
Watchlist must have a valid name.
Description (optional)
0/300
Notifications Settings
Public content (accessible by all Finder users)

Add to List

    Notifications settings

    Set Notifications
    Off
    Select notifications to recieve tooltip-info
    Select all

    Email Alerts

    Receive notifications via email

    No Notifications are selected

    Would you like to select any notifications?
    Hey #USER_FULLNAME#!
    Claim #COMPANY_NAME#’s profile to become an administrator with editing privileges in
    #COMPANY_NAME#’s page on Startup Nation Finder

    The invitation to claim the profile was originally sent to

    or  

    Hey #USER_FULLNAME#!
    Claim #COMPANY_NAME#’s profile to become an administrator with editing privileges in
    #COMPANY_NAME#’s page on Startup Nation Finder

    Suggest Edits

    Let us know what you think is inaccurate or missing.
    We will check it out and update the profile if needed.

    Claim Profile

    Please provide us the following information. Note that you need to have an email in this organization in order to claim the profile.

    Create Free Account
    Lock Icon
    Lock Icon
    8 Characters, Uppercase letter (A-Z),
    Lowercase letter (a-z), Digit (0-9)
    Lock Icon
    Passwords do not match
    Already have an account? Sign In
    Or continue with

    Verify your email

    We’ve sent a verification link to email@email.com
    Sign in
    Lock Icon
    Lock Icon
    Reset password
    Don't have an account? Create Account
    Or continue with

    Check your mailbox

    We sent you an email with further instructions to
    email@email.com

    Do not forget to check your spam folder

    Didn’t get the email? Resend email or Contact us

    Password must contain at least 8 characters, one digit, one uppercase and one lowercase letter.

    Save Search

    Dynamic List | Current Companies undefined
    Auto-updated as companies match your search. Ideal for tracking a market of interest
    Search Description
    undefined
    Search must have a valid name.
    Receive notifications via email

    Rename Search

    Search must have a valid name.
    Delete Saved Search Confirmation
    search will be permanently removed from Finder.
    News Analysis
    snackbar-icon
    title
    message
    Home > Multinationals > Novartis
    Claimed by owner Last Update Apr 27, 2026 Suggest Edits Claim Profile
    Claimed by owner
    Novartis

    Novartis

    Pharmaceuticals • Switzerland

    PUBLIC on SIX on Apr, 1995
    Terms of Use
    Novartis
    About
    Portfolio Exits
    Israeli Portfolio
    News
    Gallery
    Apr 28, 2026
    finance.yahoo.com
    Dermal Mycosis Market Research Report 2025-2026 & 2035, Competitive Analysis of Bayer, Kenvue, Karo Healthcare, Novartis, Glenmark Pharmaceuticals, Sun Pharma, Teva, and Sandoz
    Apr 26, 2026
    finance.yahoo.com
    Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market
    Apr 23, 2026
    finance.yahoo.com
    Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma
    Mar 31, 2026
    finance.yahoo.com
    TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
    Mar 3, 2026
    finance.yahoo.com
    7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
    #Product Stage #FDA approved/pending approval
    Nov 18, 2025
    finance.yahoo.com
    Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
    Sep 18, 2025
    finance.yahoo.com
    RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
    #Acquisition
    Aug 21, 2025
    finance.yahoo.com
    [Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
    Aug 13, 2025
    finance.yahoo.com
    Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
    Jul 31, 2025
    finance.yahoo.com
    Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
    #Product Stage
    Jul 18, 2025
    finance.yahoo.com
    Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
    May 1, 2025
    finance.yahoo.com
    Biotech Alert: Searches spiking for these stocks today
    #Product Stage #FDA approved/pending approval
    Dec 24, 2018
    www.calcalistech.com
    Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
    #Investment
    Dec 23, 2018
    en.globes.co.il
    Ayala signs licensing deal with Novartis for blood cancer drug
    #Investment #Partners
    Oct 17, 2018
    en.globes.co.il
    Novartis to invest in $60m Gamida Cell Nasdaq IPO
    #Public Trading #Investment
    Feb 15, 2015
    www.globes.co.il
    Novartis seeks new Israeli technologies
    #Investment #Partners
    Dec 15, 2009
    www.haaretz.com
    Optonol: Reaping $180m from a device the size of a grain of rice
    #Acquisition

    About

    Novartis AG focuses its business on three divisions: pharmaceuticals, eye care (Alcon), and generics (Sandoz). These three divisions are supported by the research organization, the Novartis Institutes for BioMedical Research, and a centralized services group, Novartis Business Services, to facilitate collaboration across the divisions and drive efficiency and productivity gains.

    In Israel, in addition to the marketing department, Novartis has a division engaged in medical research and development of new drugs and a wide range of clinical research activities. In 2009, Alcon, a subsidiary of Novartis, acquired Optonol, a company that develops devices for ophthalmologic applications and glaucoma surgery. Since its acquisition, Optonol operates as a subsidiary of the company.

    Novartis also operates in Israel a Cyber Security research center. Novartis is also present in Israel, through its innovation center BIOME.

    Founded

    In Israel Since

    Employees Worldwide

    Employees In Israel

    Market Cap

    Market Cap Update

    1/2026

    Country

    Switzerland

    News

      (17)
    Apr 28, 2026
    finance.yahoo.com
    Dermal Mycosis Market Research Report 2025-2026 & 2035, Competitive Analysis of Bayer, Kenvue, Karo Healthcare, Novartis, Glenmark Pharmaceuticals, Sun Pharma, Teva, and Sandoz
    Apr 26, 2026
    finance.yahoo.com
    Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market
    Apr 23, 2026
    finance.yahoo.com
    Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma
    Mar 31, 2026
    finance.yahoo.com
    TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
    Mar 3, 2026
    finance.yahoo.com
    7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036
    #Product Stage #FDA approved/pending approval
    Nov 18, 2025
    finance.yahoo.com
    Microscopic Polyangiitis Market Research Report 2025-2035, Competitive Analysis of Roche, Amgen, Teva, Novartis, Baxter, Amerigen Pharma, InflaRx, Biogen, Pfizer, Celltrion
    Sep 18, 2025
    finance.yahoo.com
    RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
    #Acquisition
    Aug 21, 2025
    finance.yahoo.com
    [Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
    Aug 13, 2025
    finance.yahoo.com
    Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
    Jul 31, 2025
    finance.yahoo.com
    Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
    #Product Stage
    Jul 18, 2025
    finance.yahoo.com
    Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
    May 1, 2025
    finance.yahoo.com
    Biotech Alert: Searches spiking for these stocks today
    #Product Stage #FDA approved/pending approval
    Dec 24, 2018
    www.calcalistech.com
    Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
    #Investment
    Dec 23, 2018
    en.globes.co.il
    Ayala signs licensing deal with Novartis for blood cancer drug
    #Investment #Partners
    Oct 17, 2018
    en.globes.co.il
    Novartis to invest in $60m Gamida Cell Nasdaq IPO
    #Public Trading #Investment
    Feb 15, 2015
    www.globes.co.il
    Novartis seeks new Israeli technologies
    #Investment #Partners
    Dec 15, 2009
    www.haaretz.com
    Optonol: Reaping $180m from a device the size of a grain of rice
    #Acquisition

    The Team

    (1)
    TV
    Tal Vardi
    Head of Digital and Innovation, Novartis Israel

    Connect with

    What is the reason for connecting? *
    Please select a reason
    Your company *
    Please fill out this field

    Your organization type *

    Please fill out this field
    Please select a type
    Your position *
    Please fill out this field
    Add invitation message
    0/300

    Sending invitation...

    Portfolio Exits

    Public Offering
    $55M
    May 2020
    Stock Exchange
    NASDAQ logo
    NASDAQ
    Valuation Undisclosed
    $55M
    Public Offering
    $50M
    Oct 2018
    Stock Exchange
    NASDAQ logo
    NASDAQ
    Valuation $210M
    $50M

    Locations

    Israel

    Totseret ha-Arets Street 6, Tel Aviv-Yafo, Israel
    Neve Ilan, Israel

    Offices Abroad

    Basel, Switzerland

    Locations

    Israel

    Totseret ha-Arets Street 6, Tel Aviv-Yafo, Israel
    Neve Ilan, Israel

    Offices Abroad

    Basel, Switzerland

    Notes

    Content Writer
    undefined
    BI Verification
    undefined
    Phone Number
    undefined
    Israel Register ID
    undefined
    Confidence Score
    undefined
    Missing Fields
    undefined
    Profile Creator
    undefined
    Profile Update
    undefined
    undefined

    Add Article

    0/500